Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Cash & Current Investments (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Cash & Current Investments for 7 consecutive years, with $82.0 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Cash & Current Investments fell 35.85% year-over-year to $82.0 million, compared with a TTM value of $82.0 million through Sep 2019, down 35.85%, and an annual FY2018 reading of $118.1 million, up 15.69% over the prior year.
  • Cash & Current Investments was $82.0 million for Q3 2019 at Larimar Therapeutics, down from $91.7 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $204.0 million in Q3 2015 and bottomed at $75.8 million in Q2 2018.
  • Average Cash & Current Investments over 5 years is $119.5 million, with a median of $106.9 million recorded in 2015.
  • Peak annual rise in Cash & Current Investments hit 177.87% in 2015, while the deepest fall reached 37.74% in 2015.
  • Year by year, Cash & Current Investments stood at $185.1 million in 2015, then tumbled by 30.2% to $129.2 million in 2016, then decreased by 21.01% to $102.1 million in 2017, then grew by 15.69% to $118.1 million in 2018, then plummeted by 30.54% to $82.0 million in 2019.
  • Business Quant data shows Cash & Current Investments for LRMR at $82.0 million in Q3 2019, $91.7 million in Q2 2019, and $104.7 million in Q1 2019.